{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:56:18Z","timestamp":1772844978074,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"DOI":"10.2146\/ajhp130632","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T13:53:25Z","timestamp":1408629205000},"page":"1450-1455","source":"Crossref","is-referenced-by-count":15,"title":["Off-label uses of alvimopan and methylnaltrexone"],"prefix":"10.1093","volume":"71","author":[{"given":"Ryan W.","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Ryan W. Rodriguez, Pharm.D., BCPS, is Clinical Assistant Professor, Drug Information Specialist, University of Illinois at Chicago College of Pharmacy, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019031208573379200_b1-0711450","volume-title":"Entereg (alvimopan) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019031208573379200_b2-0711450","volume-title":"Relistor (methylnaltrexone bromide) package insert","year":"2012"},{"key":"key\n\t\t\t\t2019031208573379200_b3-0711450","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2146\/ajhp080445","article-title":"Alvimopan for postoperative ileus","volume":"66","author":"Bream-Rouwenhorst","year":"2009","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019031208573379200_b4-0711450","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/11598000-000000000-00000","article-title":"Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone","volume":"32","author":"Gatti","year":"2012","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t2019031208573379200_b5-0711450","unstructured":"Cubist Pharmaceuticals. Cubist announces FDA approval for expanded use of Entereg. www.cubist.com\/news\/110-cubist_announces_fda_approval_for_expanded_use_of_entereg_r (accessed 2013 Dec 21)."},{"key":"key\n\t\t\t\t2019031208573379200_b6-0711450","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ajog.2006.01.039","article-title":"A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy","volume":"195","author":"Herzog","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"key\n\t\t\t\t2019031208573379200_b7-0711450","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10350-005-0035-7","article-title":"Phase III trial of alvimopan, a novel, peripherally acting, \u03bc opioid antagonist, for postoperative ileus after major abdominal surgery","volume":"48","author":"Delaney","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"key\n\t\t\t\t2019031208573379200_b8-0711450","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/01.sla.0000141158.27977.66","article-title":"Alvimopan, a novel, peripherally acting \u03bc opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus","volume":"240","author":"Wolff","year":"2004","journal-title":"Ann Surg"},{"key":"key\n\t\t\t\t2019031208573379200_b9-0711450","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa010564","article-title":"Selective postoperative inhibition of gastrointestinal opioid receptors","volume":"345","author":"Taguchi","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031208573379200_b10-0711450","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00464-005-0104-y","article-title":"Alvimopan, a peripherally acting muopioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study","volume":"20","author":"Viscusi","year":"2006","journal-title":"Surg Endosc"},{"key":"key\n\t\t\t\t2019031208573379200_b11-0711450","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/DCR.0b013e3182092bde","article-title":"Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials","volume":"54","author":"Yu","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"key\n\t\t\t\t2019031208573379200_b12-0711450","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.pain.2007.11.008","article-title":"Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain","volume":"137","author":"Webster","year":"2008","journal-title":"Pain"},{"key":"key\n\t\t\t\t2019031208573379200_b13-0711450","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jpain.2010.06.012","article-title":"A randomized, placebo-controlled phase 3 trial (study SB-767905\/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain","volume":"12","author":"Jansen","year":"2011","journal-title":"J Pain"},{"key":"key\n\t\t\t\t2019031208573379200_b14-0711450","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpain.2010.06.013","article-title":"A randomized, placebo-controlled phase 3 trial (study SB-767905\/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain","volume":"12","author":"Irving","year":"2011","journal-title":"J Pain"},{"key":"key\n\t\t\t\t2019031208573379200_b15-0711450","unstructured":"GlaxoSmithKline. GSK and Adolor announce preliminary results from phase 3 safety study of alvimopan (Entereg\/Entrareg). www.gsk.com\/media\/press-releases\/2007\/gsk-and-adolor-announce-preliminary-results-from-phase-3-safety-study-of-alvimopan-enteregentrareg.html (accessed 2013 Apr 10)."},{"key":"key\n\t\t\t\t2019031208573379200_b16-0711450","unstructured":"Food and Drug Administration. Entereg (alvimopan) OBD study GSK014 safety findings. www.fda.gov\/ohrms\/dockets\/ac\/08\/slides\/2008-4336s1-04-Adolor-Mortensen.pdf (accessed 2013 Apr 10)."},{"key":"key\n\t\t\t\t2019031208573379200_b17-0711450","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jpain.2010.11.008","article-title":"Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","volume":"12","author":"Michna","year":"2011","journal-title":"J Pain"},{"key":"key\n\t\t\t\t2019031208573379200_b18-0711450","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jval.2010.11.003","article-title":"Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms","volume":"14","author":"Iyer","year":"2011","journal-title":"Value Health"},{"key":"key\n\t\t\t\t2019031208573379200_b19-0711450","volume-title":"Cardiac safety of subcutaneous methylnaltrexone: results from a pooled safety analysis and a case-control analysis in noncancer pain patients with opioid-induced constipation","author":"Rauck"},{"key":"key\n\t\t\t\t2019031208573379200_b20-0711450","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpain.2004.12.001","article-title":"Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction\u2014a 21-day treatment-randomized clinical trial","volume":"6","author":"Paulson","year":"2005","journal-title":"J Pain"},{"key":"key\n\t\t\t\t2019031208573379200_b21-0711450","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jama.283.3.367","article-title":"Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial","volume":"283","author":"Yuan","year":"2000","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019031208573379200_b22-0711450","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mayocp.2011.11.014","article-title":"Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients","volume":"87","author":"Sawh","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019031208573379200_b23-0711450","unstructured":"Clinicaltrials.gov. Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit (MOVE-IT). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01050595 (accessed accessed 2013 Mar 21)."},{"key":"key\n\t\t\t\t2019031208573379200_b24-0711450","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jhm.943","article-title":"Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery","volume":"7","author":"Anissian","year":"2012","journal-title":"J Hosp Med"},{"key":"key\n\t\t\t\t2019031208573379200_b25-0711450","first-page":"6298","article-title":"Re: alvimopan provides rapid gastrointestinal recovery without nasogastric tube decompression after radical cystectomy and urinary diversion","volume":"19","author":"Huang","year":"2012","journal-title":"Can J Urol"},{"key":"key\n\t\t\t\t2019031208573379200_b26-0711450","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/IJWH.S46519","article-title":"Is a bowel resection necessary for deep endometriosis with rectovaginal or colorectal involvement?","volume":"5","author":"Aci\u00e9n","year":"2013","journal-title":"Int J Womens Health"},{"key":"key\n\t\t\t\t2019031208573379200_b27-0711450","unstructured":"Food and Drug Administration. Entereg risk evaluation and mitigation strategy. www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm129511.pdf (accessed 2013 Mar 27)."},{"key":"key\n\t\t\t\t2019031208573379200_b28-0711450","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejpain.2005.03.008","article-title":"Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain","volume":"10","author":"Slappendel","year":"2006","journal-title":"Eur J Pain"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/17\/1450\/28048805\/ajhp1450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T05:39:20Z","timestamp":1650001160000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/17\/1450\/5110942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130632","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9,1]]},"published":{"date-parts":[[2014,9,1]]}}}